$Fractyl Health (GUTS.US)$
Revolutionary One-Time GLP-1 Gene Therapy Shows Promise in Diabetes Treatment, Fractyl Reports

$Fractyl Health (GUTS.US)$
Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
Monday, 28th April at 4:30 pm
BURLINGTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ: GUTS) ("the Company"), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type ...

$Fractyl Health (GUTS.US)$
Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation
Tuesday, 1st April at 7:00 am
New REVEAL-1 study results show early signs of weight maintenance after GLP-1 discontinuation
REMAIN-1 pivotal study now more than 50% enrolled; midpoint data analysis anticipated in Q3 2025
BURLINGTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ: GUTS) ("the Company"), a metabolic t...

$Fractyl Health (GUTS.US)$
Revolutionary Device Cuts Post-GLP-1 Weight Regain by 60% in Breakthrough Study

$Fractyl Health (GUTS.US)$
Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025
Friday, 31st January at 8:01 am
Prioritizing Revita's clinical development on weight maintenance post-GLP-1 withdrawal in response to significant patient and physician demand in ongoing REMAIN-1 pivotal study; anticipate midpoint data analysis in Q2 2025 a...

$Fractyl Health (GUTS.US)$
stay away from this app alert

$Fractyl Health (GUTS.US)$
Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort
Monday, 13th January at 7:00 am
Company also announces strong enrollment progress for REMAIN-1 weight maintenance pivotal study
High demand from patients and physicians indicates significant interest in REMAIN-1 study and GLP-1 discontinuation; mid-point analysis on-track and anticipa...

$Fractyl Health (GUTS.US)$
Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
Thursday, 12th December at 7:00 am
RJVA-001 was successfully delivered in large animal Yucatan pig models at low total viral dose
Results confirm ability to directly target pancreas with novel delivery catheter and rout...

$Fractyl Health (GUTS.US)$ BURLINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced it will present new preclinical data from its Rejuva platform at the 2024 Poster Session of the 22nd World Congress Insulin Resistance, Diabetes & Cardiovascular Disease...

$Fractyl Health (GUTS.US)$ Fractyl Health: Results Show Sustained Maintenance of Weight Loss, Blood Sugar Levels at Week 13 in Dio Mice Given Rjva-001 & Continuing High Fat Diet